BE1024990B1 - Composition for use as a wound dressing - Google Patents

Abstract

A composition for use as a wound dressing for the treatment, reduction and / or prevention of scar formation which comprises the following components: a non-volatile siloxane compound; a volatile siloxane compound; optionally a crosslinked siloxane compound; an organosiloxysilicate and / or an organosilsesquioxane compound; a glycerol (C12-C26) ester compound; optionally at least one humectant, optionally in admixture with water, and optionally at least one pharmaceutical agent for the prevention or treatment of scars.

Description

PATENT OF THE INVENTION

Priority date: 24/08/2016

International classification: A61L 26/00

Registration number: BE2017 / 5566

Registration date: 17/08/2017

Owner:

DROSSAPHARM AG 4144, ARLESHEIM Switzerland

Inventor:

GARO Florian 4334 SISSELN Switzerland

LUTZ Jürg

4102 BINNINGEN Switzerland

IMBODEN Roger 4142 MUNICHSTEIN Switzerland

Composition for use as a wound dressing

A composition for use as a wound dressing for the treatment, reduction and / or prevention of scarring, which contains the following components: a non-volatile siloxane compound; a volatile siloxane compound; optionally a cross-linked siloxane compound; an organosiloxysilicate and / or an organosilsesquioxane compound; a glycerol (C12-C26) ester compound; optionally at least one humectant, optionally in a mixture with water, and optionally at least one active pharmaceutical ingredient for the prevention or treatment of scars.

BELGIAN INVENTION PATENT

FÖD Wirtschaft, K.M.B., Mittelstand & Publication number: 1024990 Energie Filing number: BE2017 / 5566

Office of Intellectual Property Boarding. Classification: A61L 26/00

Date of issue: 13/09/2018

The Minister for Enterprise

Due to the Paris Treaty of March 20, 1883 for the protection of industrial property;

Introduced under the Act of March 28, 1984 on Inventive Patents, Article 22, for applications prior to September 22, 2014;

Based on Title I “Invention Patents” of Book XI of the Economic Code, Article XI.24, introduced for applications from September 22, 2014;

Based on the royal decree of December 2, 1986 on the registration, granting and maintenance of patents for invention, Article 28;

Recorded on 17/08/2017 at the Intellectual Property Office based on the protocol.

Considering that for patent applications that fall within the scope of Title 1, Book XI, of the Economic Code, in accordance with Article XI.19, Section 4, second paragraph, of the Economic Code, if the patent application is the subject of a search report in which a lack of unity of invention within the meaning of paragraph 1 is mentioned, and if the applicant does not limit his application and does not file a divisional application in accordance with the search report, the granted patent will be limited to the claims for which the search report was created.

DECIDES:

Article 1. - An invention patent is granted to:

DROSSAPHARM AG, Birsweg 1 P.O.Box 348, 4144 ARLESHEIM Switzerland;

represented by :

OFFICE KIRKPATRICK S.A., Avenue Wolfers 32, 1310, LA HULPE;

for a period of 20 years, subject to the payment of the annual patent fees mentioned in Article XI.48, §1 of the Economic Code, for: composition for use as a wound dressing.

INVENTOR:

GARO Florian, Fasanenweg 16, 4334, SISSELN;

LUTZ Jürg, Leonhard Bartenschlag-Strasse 3, 4102, BINNINGEN;

IMBODEN Roger, Im Link 9B, 4142, MUNICHSTEIN;

PRIORITIES) :

24/08/2016 CH 01084/16;

SEPARATION:

Partial application of the previous application: Date of filing of the previous application:

Article 2. - This patent is granted without any prior examination of the patentability of the invention, without guaranteeing the merit of the invention or the accuracy of its description, and at the own risk of the patent applicant (s).

Brussels, 13/09/2018, in special representation:

BE2017 / 5566

Composition for use as a wound dressing

The present invention relates to a composition for use as a wound dressing for treating scars and for reducing and / or preventing scarring, comprising at least one non-volatile linear siloxane compound, at least one volatile siloxane compound, at least one organosiloxysilicate and / or an organosilsesquioxane compound , and a viscosity-changing compound (flow agent), such as a glycerol (C12-C26) ester compound, these as

Monoester, diester and / or triester compound can be present. The composition can also be cross-linked

Contain siloxane polymer and other additives.

Compositions that can be used as a wound dressing for

Reduction and / or prevention of scarring are known per se. Such compositions are described, for example, in US Pat. No. 5,741,509 and US Pat. No. 8,021,683 B2 or in EP 2 211 919 B1 and preferably contain siloxane compounds.

The composition described in US Pat. No. 5,741,509 contains, for example, a non-volatile liquid siloxane compound, pyrogenic silica and a volatile diluent. The composition described in US Pat. No. 8,021,683 B2 additionally contains a cross-linked siloxane polymer. EP 2 211 919 B1 describes a composition which comprises a selected occlusive silicone gel and a

Contains polymethylsilesquioxane. These compositions contain a volatile diluent and must therefore, especially with regard to the changing viscosity during the curing process, be sufficiently flexible that the composition applied to the body surface, for example in the form of an ointment, a gel or oil, during the evaporation of the fleeting

Diluent forms an evenly distributed wound dressing, which has sufficient strength and adhesion

BE2017 / 5566 has the skin and is still easy to remove. However, the known compositions adhere only insufficiently to the skin and, especially in the presence of water, do not have sufficiently high water-repellent properties. This means that previous formulations are simple and easy to wash off. As a result, the

Wound dressings are often renewed, which can lead to unnecessary irritation. The wound dressing that forms is also not impermeable, i.e. the transepithermal

Water loss from the skin is due to the wound dressing

Minimum is limited but not completely prevented. Also, the known compositions are usually transparent and translucent due to the bad

Contrast between the skin and the composition that

Application and dosage of the composition on the

Scar tissue can complicate. Furthermore, the known compositions have hardly any cosmetic care properties per se.

There is therefore a need for compositions with improved properties, particularly with regard to

Development of an improved barrier function (occlusive effect), with regard to an improved resistance to the

Washable with water and for long-term care of the damaged tissue.

It has now been found that the composition according to the invention described here surprisingly does not have these disadvantages, or has them significantly less.

The composition according to the invention thus has an improved barrier function, in particular with respect to water.

By incorporating a humectant in the

Silicone matrix, the water loss can surprisingly be additionally reduced by the composition according to the invention, in that epithermally escaping

Water of the composition according to the invention

BE2017 / 5566 is absorbed and returned to the skin. An increased storage capacity of water can therefore be achieved with the composition according to the invention, which in turn results in increased epithelization and a

Accelerates wound healing. Furthermore, the composition according to the invention has improved applicability and spreadability or spreadability on the skin, since the composition according to the invention is not transparent and is only slightly tacky. The inventive

Surprisingly, the composition also exhibits improved resistance to washability

Water on. This property is attributed to the incorporation of long chain fatty alcohols, which is an improved one

Connection between the skin and the invention

Composition causes. However, the invention is not bound by this explanation.

The present invention is formulated in the claims. In particular, the present invention relates to a composition for use as a wound dressing

Scar reduction and / or prevention, comprising:

(i) a non-volatile siloxane compound, preferably a linear or cyclic polydimethylsiloxane, with a weight fraction in the range from 5% to 70% by weight;

(ii) a volatile siloxane compound, preferably a linear and / or cyclic dimethylsiloxane compound, with a weight fraction in the range from 10% by weight to 80% by weight; and (iii) optionally a crosslinked siloxane compound, preferably a crosslinked dimethylsiloxane compound, with a weight fraction in the range from 1% by weight to 15% by weight;

characterized in that this composition

BE2017 / 5566 (iv) contains at least one organosiloxysilicate and / or an organosilsesquioxane compound, the proportion by weight of the organosiloxysilicate compound in the composition in the range from 5% by weight to 40% by weight, and the proportion by weight of the organosilsesquioxane compound in the composition ranges from 2% to 30% by weight;

(v) at least one glycerol (C ₁₂ -C ₂ 6) Esterverbindung, preferably a monoester, diester and / or triester compound, and these glycerol Esterverbindung in the composition in an amount ranging from 0.5 wt.% to 20.0 wt .-% is present; and (vi) optionally at least one humectant, as a single compound or as a mixture of such compounds, optionally in a mixture with water, preferably in an amount of 0.1% by weight to 5.0% by weight; and (vii) optionally contains at least one pharmaceutical active ingredient for the prevention or treatment of scars.

The present invention also relates to the composition according to the invention, which additionally contains at least one humectant and water and / or at least one pharmaceutical active ingredient for the

Contains prevention or treatment of scars.

The present invention also relates to a method for

Production of the composition according to the invention.

The present invention further relates to

Use of the composition according to the invention as

Wound dressing to treat scars and to reduce and / or prevent scarring.

BE2017 / 5566

The present invention also relates to a method for

Treatment of scars and to reduce or prevent scarring, characterized in that a composition according to the invention is applied as a wound dressing to an injured area of human skin. These

Treatment of scars and prevention of scar formation particularly affect hypertropic, atropic scars

Scars or keloid scars, as a result of a cut or

Skin lesion.

The non-volatile linear siloxane compound [component (i)] preferably corresponds to the linear compound of the general formula (I):

RR RR

R1-Si-O-I-Si-O-I-I-Si-O-I-SI-R1 0

I L I JmL I Jn |

RR R1 R where

R independently of one another, optionally with chlorine or

Fluorine-substituted alkyl radical having 1-4 C atoms or phenyl, preferably methyl, ethyl, propyl, or phenyl, preferably methyl;

RI is independently one of the meanings of R,

Hydrogen or hydroxyl, preferably methyl, ethyl,

Propyl, or phenyl, preferably methyl;

m and n each independently represent an integer of

10 to 2000, preferably an integer from 20 to 1500, preferably an integer from 40 to 1000, preferably an integer from 60 to 1000, preferably an integer from to 800, in particular an integer from 80-800; and the groups [-Si (R) (R) O-] and [-Si (R) (R ^ O-]) are arranged in the molecule in any order.

BE2017 / 5566

This non-volatile linear siloxane compound [component (i)] is preferably a linear polydimethylsiloxane compound.

The proportion by weight of the non-volatile siloxane compound [component (i)] in the composition according to the invention is preferably in the range from 5% by weight to 70% by weight,

preferably in the Area from 10th Weight -% to 50 Wt ^-.% _F preferably in the Area from 10th Weight -% to 40 Wt .-% _f and preferably in the Area from 10th Weight -% to 30th Wt .-% _f each

based on the total weight of the composition.

The average molecular weight of the non-volatile linear siloxane compound [component (i)] is preferably in the range from 1,000 to 300,000 Da (Dalton = atomic mass unit), preferably in the range from 1,500 to 250,000 Da, preferably in Range from 2,500 to 200,000 Da, preferably in the range from 3,000 to 120,000 Da, preferably in the range from 5,000 to 100,000 Da.

The kinematic viscosity at 25 ° C. of the individual non-volatile linear siloxane compound [as part of component (i)] is preferably in the range from 50 cSt (centistokes) to 120,000 cSt, preferably in the range from 50 cSt to 80,000 cSt, preferably in the range from 100 cSt to 50,000 cSt, and preferably in the range from 100 cSt to 30,000 cSt (Centistokes), measured according to ASTM D-445, IP71, using a glass capillary viscometer or a rotary viscometer.

The kinematic viscosity at 25 ° C of the non-volatile linear siloxane component [component (i)] is preferably optimized by mixing two or more non-volatile linear siloxane compounds. For example, 20 parts of a non-volatile linear siloxane compound with a viscosity at 25 ° C of

BE2017 / 5566

100 cSt and 1.5 parts of a non-volatile linear

Siloxane compound with a viscosity at 25 ° C of 12'500 cSt a very good mixture, usable as component (i), both in the starting mixture and for the hardened wound dressing.

Such non-volatile siloxane compounds are commercially available, for example as Dimethicone from Dow

Corning Inc., USA, such as Dimethicone, Q7-9120-Silicone fluid,

CAS number 63148-62-9, with a viscosity of 12'500 cSt (Centistokes) at 25 ° C.

It is known to those skilled in the art that the total mass of the stated linear or cyclic siloxane compound [e.g.

referred to as component (i)] in each case a mixture of polymeric individual molecules with different ones

Represents molecular weights. The specified values of n for the total mass of a component [e.g. of component (i)] thus denote the average n values of the corresponding mixture of polymeric individual molecules.

The same applies analogously to the others specified here

Siloxane compounds, e.g. which as component (ii) or

Component (iii) designated siloxane compounds.

The volatile linear or cyclic siloxane compound [component (ii)] preferably corresponds to the general formula (II),

R R R

I r I i I

R'— Si ^- O —— Si ^- O —— Si ^- R '

I ^L I ^Jn I

R R R (II)

BE2017 / 5566 wherein R and R 'independently of one another have an alkyl radical

1-4 carbon atoms, preferably methyl; and n is zero or an integer from 1-5, the two terminal substituents for the cyclic compound

R 'together the direct bond, i.e. a cyclic

Polysiloxane compound.

The proportion by weight of this volatile siloxane compound in the composition according to the invention is preferably in

Range from 10% to 80% by weight; preferably in the range of 15% to 70% by weight; preferably in the range of 20

% By weight to 60% by weight; preferably in the range from 20% by weight to 55% by weight; and preferably in the range from 25% by weight to

% By weight, based in each case on the total weight of the composition.

The volatile siloxane compound, corresponding to formula (II), is a liquid compound with a sufficiently high level

Vapor pressure at room temperature (25 ° C), so that this volatile siloxane compound within a short time after application of the composition according to the invention to the skin

Time evaporates and an evenly distributed coherent

Layer remains.

The volatile linear siloxane compound [component (ii)] is preferably a linear dimethylsiloxane compound such as hexamethyldisiloxane, octamethyltrisiloxane,

Decamethyltetrasiloxane and / or dodecamethylpentasiloxane;

preferably octamethyltrisiloxane and / or decamethyltetrasiloxane.

The volatile cyclic siloxane compound [component (ii)] is preferably a dimethylcyclosiloxane compound such as hexamethylcyclotrisiloxane,

Octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane,

Dodecamethylcyclohexasiloxane. Hexa9 are preferred

BE2017 / 5566 methylcyclotrisiloxane, octamethylcyclotetrasiloxane,

Decamethylcyclopentasiloxane. Octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane are particularly preferred.

The volatile siloxane compounds can be used in any mixture with the other siloxane compounds present, in particular the viscosity of the individual components or the preparation of the

To optimize composition and its curing. This is within the skill of the artisan.

Such volatile linear or cyclic siloxane compounds are known per se and are commercially available, for example from Dow Corning Inc., USA, such as Dimethicone, TI-1050 Fluid, CAS no. 141-62-8, with a viscosity of 1.5 cSt (Centistokes) at 25 ° C, containing linear decamethyltetrasiloxane or Dow Corning 244, containing cyclic octamethylcyclotetrasiloxane.

The crosslinked siloxane compound [component (iii)] which may be present is preferably a crosslinked dimethylsiloxane compound and corresponds in that

Basic structure preferably of the above formula (I) or the above formula (II), these linear or cyclic basic structures being cross-linked two-dimensionally and / or three-dimensionally. In such a crosslinked siloxane compound, a substituent RI or more substituents RI in the formula (I) or a substituent R or more substituents R in the formula (II) each represents a radical of the formula (purple) or (Illb) or (IIIc):

R

I —O-Si-O— (purple); R —O-Si-O— (Illb)

O —O-Si-O— (IIIc) O

BE2017 / 5566 where these residues (purple), (Illb) and / or (IIIc) are each the

Form a bridge to another polysiloxane compound of formula (I) and / or formula (II).

The chemical formulas (I), (II), (purple), (Illb) and (IIIc) for the siloxane compounds are known to the person skilled in the art. The chemical formulas for the siloxane compounds are given here for the sake of explanation and do not limit the scope of the siloxane compounds which can be used according to the invention. For example, the siloxane compounds of the formula (I) or of the formula (II) can also be cross-linked two-dimensionally and / or three-dimensionally via an alkylene radical and thus form a crosslinked siloxane compound.

The cross-linked siloxane compound [component (iii)] which may be present is also referred to as a siloxane elastomer and is preferably a compound with thixotropic properties. The proportion by weight of this crosslinked siloxane compound [component (iii)] in the composition according to the invention is preferably in

Range from 1% by weight to 15% by weight, preferably in the range from 1% by weight to 10% by weight, preferably in the range from 2

% By weight to 10% by weight, and preferably in the range of 2

% By weight to 7.5% by weight, in each case based on the total weight of the composition.

The molecular weight of the crosslinked siloxane compound [component (iii)] which may be present is preferably higher than 200,000 Da (dalton), preferably higher than 250,000 Da, and preferably higher than 300,000 Da and preferably has a kinematic viscosity (at 25 ° C) in

Range from 200 Ό00 cSt to 900 Ό00 cSt.

For the processing of the crosslinked siloxane compound [component (iii)] which may be present, the crosslinked siloxane compound is preferably mixed with the

BE2017 / 5566 non-volatile linear siloxane compound [component (i)] and / or with the volatile siloxane compound [component (ii)], so that an easily editable mixture with a comparatively low viscosity results. This is problem-free for the specialist.

The composition according to the invention contains at least one organosiloxysilicate and / or an organosilsesquioxane compound [component (iv)]. The organosiloxysilicate compound is preferably a polyalkylpolysiloxysilicate, preferably a polymethylpolysiloxysilicate, preferably a trimethylsiloxysilicate.

Such Trimethylsiloxysilikate for example, correspond to the formula: [(CH _{3) 3} SiO _{2/2] x.} [SiO ₂ ] _y , where x is a number from 1 to 3 and y is a number from 0.5 to 8. In the

The grain size distribution of the organosiloxysilicate compounds is preferably 75% of the particles smaller than 44

Micrometer.

The proportion by weight of the organosiloxysilicate compound

Component (iv) in the composition according to the invention is preferably in the range from 5% by weight to 35% by weight;

preferably in the range of 5% to 30% by weight;

preferably in the range of 10% to 25% by weight; preferably in the range from 10% by weight to 20% by weight, in each case based on the total weight of the composition.

The organosilsesquioxane compound [component (iv)] is preferably a polyalkylsilsesquioxane

Polyarylsilsesquioxane or a polyalkoxysilsesquioxane, preferably a polyalkylsilsesquioxane, preferably a (C ₃₀ -C ₄₅ ) alkyldimethylsilyl-polyalkylsilsesquioxane, preferably a (C ₃₀ -C45) alkyldimethylsilyl-polypropylsilsesquioxane.

BE2017 / 5566

Such organosilsesquioxane compounds as solids are known per se and correspond to the formula [RSiO _{3/4] m,} wherein R is independently alkyl, aryl or alkoxyl, and m is preferably 6, 8, 10 or 12, or an even higher number mean. The organosilsesquioxane compound preferably has a melting point in the range from 60 ° C. to 75 ° C., preferably in the range from 63 ° C. to 71 ° C., the

Compound preferably represents a waxy solid.

The weight fraction of the organosilsesquioxane compound

Component (iv) in the composition according to the invention is preferably in the range from 2% by weight to 30% by weight;

preferably in the range of 5% to 25% by weight;

preferably in the range of

% By weight to 20% by weight, in each case based on the total weight of the composition.

The composition according to the invention further contains a glycerol (Ci ₂ -C ₂₆ ) ester compound [component (v)]. These individual compounds or a mixture of these compounds act as flow agents (rheology modifiers).

This glycerol (Ci ₂ -C ₂₆ ) ester compound can be used as a monoester,

Diester and / or triester compound are present, preferably as a glycerol (C ₁₃ -C ₂₄ ) ester compound. Glycerol behenate is preferred. The fatty acid content can also be unsaturated

Contain fatty acids.

Glycerol (C ₁₂ -C ₂₆ ) ester compounds are known per se. These are usually present as mixtures, in particular as a mixture of the monoester, diester and / or triester compounds. Glycerol behenate, which is the mono-, di- or triester of glycerol and behenic acid (C ₂ iH ₄₃ COOH; also called docosanic acid) or as a mixture, is particularly preferred13

BE2017 / 5566 ser ester is present. A mixture is preferably used which consists predominantly of the diester compound.

These glycerol (C ₁₂ -C ₂ 6) ester compounds are surprisingly readily miscible with the siloxane compounds used and bring about desired changes in the viscosity of the composition according to the invention. The glycerol (C12-C26) ester compounds also have the advantage, together with the

To form silicone compounds a dispersion with highly refractive properties, so that the composition according to the invention is white and non-transparent. This gives the composition according to the invention further advantageous properties, in particular for the

Apply to the skin as described at the beginning.

These glycerol ester compounds and their preferred forms in the composition according to the invention are preferably in the range from 0.5% by weight to 20.0% by weight; preferably in

Range from 2.0% to 15% by weight; and preferably in

Range from 4.0% by weight to 10.0% by weight, present, calculated in each case on the total weight of the inventive

Composition.

The glycerol (C12-C26) ester compound is preferably dispersed in the non-volatile siloxane compound and also increases its viscosity. In this way, the viscosity of the composition according to the invention, in combination with the other components present, can be adjusted as desired, so that the composition is, for example, an easily usable ointment (cream), a gel or an oil.

The composition according to the invention optionally contains at least one humectant [component (vi)], as a single compound or as a mixture of such compounds, optionally in a mixture with water. Surprisingly, the presence of at least one humectant shows

BE2017 / 5566 and the presence of at least one humectant mixed with water, a very positive effect in the

Form that the healing effect is significantly improved due to the increased epithelialization and due to the increased occlusive effect. This, although it was assumed that the presence of a humectant and water in the composition according to the invention should be avoided as far as possible.

Suitable humectants are, for example, panthenol (CAS No. 81-13-0), hyaluronic acid (CAS No. 9004-61-9) and

Salts of this compound, and also known chemically related glycosaminoglycan compounds, polyethylene glycol (PEG), sorbitol, glycerol, urea, propylene glycol,

Pyrrolidone carboxylic acid and its salts, lactic acid and

Lecithins.

Such humectants are preferably in an amount of 0.1% by weight to 5.0% by weight, preferably in one

Amount of 0.1 wt .-% to 3.0 wt .-%, preferably in an amount of 0.1 wt .-% to 2.0 wt .-%, calculated on the total weight of the composition, present, these humectants the water content in the

Allow composition. The water (mixed with the

Humectant) is finer in the silicone mass

Droplets dispersed in an amount up to about 5.0

% By weight, preferably from 0.1% by weight to 5.0% by weight, preferably in an amount from 0.5% by weight to 4.0% by weight, calculated on the total weight of the composition.

Used as a humectant, for example

Hyaluronic acid, this is mixed with water, preferably before adding to the composition. This previously made mixture is then used as a humectant (i.e.

including water) of the silicone phase directly before it

Thickening added and even in this silicone phase

BE2017 / 5566 distributed. Subsequently, the silicone phase obtained is mixed with component (v) and optionally further components and homogenized. The so produced

Silicone phase preferably contains the humectant in

Shape of finely divided droplets, with an average

Droplet size in the range from 1pm to 10pm, the emulsion obtained remaining stable without further addition of emulsifiers or components stabilizing the emulsion.

This emulsion is then finished by adding the other components.

The composition according to the invention may optionally contain one or more pharmaceutically active compounds [component (vii)] for the prevention or treatment of

Scars included. This pharmaceutically active compound preferably has an antibacterial, anti-inflammatory, antiviral and / or antifungal effect, preferably an antibacterial and / or anti-inflammatory effect.

Such pharmaceutically active substances known per se are preferably soluble in organic solvents and are preferably used in an amount in the range of approximately

0.1 wt .-% to 5 wt .-%, based on the total weight of the

Composition used. Surprisingly, it has been shown that the present invention

Composition even without the presence of such pharmaceutically active ingredients is an excellent curative

Has effect.

The composition according to the invention can optionally additionally contain organic compounds which act as thickeners / flow agents or a mixture of such compounds. Such a mixture of compounds consists, for example, of stearyl alcohol (Ci ₈ H ₃₈ O) and

Trimethylstearyloxysilane (C2iH ₄₆ OSi). This mixture is known per se and is also referred to as “silky wax”.

BE2017 / 5566

The composition according to the invention can optionally also contain an inorganic compound or a mixture of such inorganic compounds selected from metal oxides,

Contain metal carbonates and / or metal bicarbonates in the form of a fine powder, preferably selected from

Zinc oxide, titanium dioxide, magnesium oxide, calcium carbonate,

Magnesium carbonate, sodium carbonate and / or sodium bicarbonate. Such a powder or powder mixture is preferably present in an amount in the range of

0.1 wt .-% to 5 wt .-%, based on the total weight of the

Composition. Preferably at least 75% of the

Particles of this powder or powder mixture

Diameter less than 44 pm (microns).

These inorganic compounds are not soluble in the composition according to the invention and thus increase their refraction. This will increase the transparency of the

Composition further reduced. Furthermore, these inorganic compounds improve the haptic, as haptic

Perception of the composition as well as that of the skin after application of the composition. Both effects surprisingly improve the applicability of the

Composition.

The composition according to the invention preferably contains at least one UV-absorbing compound, preferably in an amount in the range from about 10% by weight to 30% by weight, based on the total weight of the composition. Such UV radiation absorbing compounds are known per se, for example bis-ethylhexyloxyphenol

Methoxyphenyltriazines, ethylhexyl methoxycinnamates,

Ethylhexyltriazone, octocrylene, butylmethoxydibenzoylmethane, methylene-bis-benzotriazolyl,

Tetramethylbutylphenol, octylsalicylates, oxybenzone,

Polysilicone-15, titanium dioxide, and zinc oxide.

BE2017 / 5566

The composition according to the invention for applications on the

Skin is preferably produced and used as an ointment or as a gel, its kinematic viscosity in the

Range from 1,000 cSt (Centistokes) to 25,000 cSt, preferably in the range from 5000 cSt to 15,000 cSt (Centistokes), measured with a device from Fisher Scientific, HAAKE

RotoVisco 1 (Ser.No. 115000029002) as further described herein.

The composition contains only the non-volatile components, i.e. the inventive

Composition without the volatile component [component (ii)], such as this after the application of the inventive

Composition on the skin after evaporation of the volatile component, preferably has a kinematic viscosity in the range from 10,000 cSt (centistokes) to 50,000 cSt, preferably in the range from 10,000 cSt (centistokes) to 20,000 cSt, measured with a device from Fisher Scientific, HAAKE RotoVisco 1 (Ser.No.

115000029002) as further described herein.

This change in viscosity occurs after the application of the composition according to the invention on the skin, due to the evaporation of the volatile component, in a few

Minutes, preferably in less than ten minutes.

The present invention also relates to a method for

Production of the composition according to the invention, which is characterized in that a non-volatile

Siloxane compound as defined in component (i);

a volatile siloxane compound as defined in the

Component (ii); an organosiloxysilicate and / or one

Organosilsesquioxane compound as defined in the

Component (iv); a glycerol (Οι ₂ -Ο ₂ 6) ester compound according to the definition of component (v), and optionally a cross-linked siloxane compound according to the definition of

Component (iii) and optionally further components,

BE2017 / 5566 which should be present in the composition, mix in any order until all components form a homogeneous composition.

A preferred method for producing the composition according to the invention is characterized in that [step (A)]: the non-volatile siloxane compound as defined in component (i); the organosiloxysilicate and / or the organosilsesquioxane compound according to the

Definition of component (iv) and the crosslinked siloxane compound which may be present according to the

Definition of component (iii), together with one another

Mixing temperature in the range from 50 ° C to 90 ° C, preferably at a temperature in the range from 70 ° C to 90 ° C, until a homogeneous composition is obtained;

then [step (B)]: the one that may be present

Humectant [component (vi)], which may have been previously mixed with water, is added to the composition obtained in step (A) and the composition thus obtained

Composition at a temperature in the range of 40 ° C to

90 ° C, preferably homogenized at a temperature in the range of 70 ° C to 90 ° C; then [step (C)]: the flow agent, if any, and any other components, if any, are added to the composition obtained in step (B) and the composition thus obtained at a temperature in the range from 30 ° C. to 50 ° C., preferably at one

Temperature in the range from 40 ° C to 50 ° C, homogenized and then allowed to cool to room temperature (20 ° C to 30 ° C); and then [step (D)]: the volatile siloxane compound according to the

Definition of component (ii) is added to the composition obtained in step (C) and the composition thus obtained

BE2017 / 5566

Composition preferably at room temperature (20 ° C to

30 ° C) homogenized.

The homogenization according to step (A), step (B) and step (C) is preferably carried out independently of one another under reduced pressure, preferably at a pressure in the range from 300 mbar to 800 mbar, preferably in the range from 400 mbar to 600 mbar, (normal pressure: 1 bar), the composition being mixed intensively in each case until a homogeneous composition is obtained.

The present invention also relates to the use of the composition according to the invention as a wound dressing for

Treatment, especially for reducing and / or

Prevention, of scarring. For this purpose, the composition according to the invention is applied uniformly to the human

Skin applied. The body heat then causes the volatile component to evaporate and the wound dressing with the necessary increased viscosity and adhesive strength forms.

The following examples illustrate the invention without limiting it.

Examples

Those described in Examples 1 to 6 below

Compositions were according to the previous in the

Description described steps (A) to (C) prepared. The given in the examples

Viscosity values were measured as follows:

Device: Fisher Scientific, HAAKE RotoVisco 1 (Ser.No.

115000029002)

Principle: plate-plate; Gap: 0.1 mm; Volume: 0.4 ml

Shear rate: 30 1 / s, constant

Measurement: after 60 seconds; Temperature: 20 ° C

BE2017 / 5566

example 1

product Viscosity, cSt (25 ° C) CAS number Amount,% by weight component (i) Polydimethyl siloxane 100 cSt 63148-62-9 25.5% Polydimethyl siloxane 12500 cSt 63148-62-9 2% component (ü) Decamethyl tetra siloxane 1.5 cSt 141-62-8 25% component (iv) Trimethylsiloxy silicate firm resin 68988-56-7 15% (C30-45) alkyldimethylsilyl polypropylsilsequioxane Mp 63-71 ° C 955920-25-9 12.5% component (v) Glycerol dibehenate Pellet 91052-55-0 10% Trimethylstearyl oxysilane Flakes 18748-98-6 5% Stearyl alcohol Flakes 112-92-5 5% Total: 100%

Component (i): non-volatile polysiloxane compound

Component (ii): volatile polysiloxane compound

Component (iv): organosiloxysilicate compound and organosilsesquioxane

Component (v): glycerol (C ₁₂ -C ₂ 6) ester compound

Example 2

Example 1 was repeated, the polydimethylsiloxane compound having a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) being reduced further to 24.5% and a component (vi) in the form of 1% panthenol (CAS No. 81-13-0) was added as a humectant.

Example 3

Example 1 was repeated, the polydimethylsiloxane compound having a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) being further reduced to 23.5% and 2% magnesium oxide (CAS No. 1309-48-4) added has been.

Example 4

Example 3 was repeated, the polydimethylsiloxane compound having a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) being reduced to 22.5% and one

BE2017 / 5566

Component (vi) in the form of 1% panthenol (CAS No. 81-13-0) were added.

Example 5

product Viscosity, cSt (25 ° C) CAS number Amount,% by weight component (i) Polydimethyl siloxane 100 cSt 63148-62-9 20% Polydimethyl siloxane 12500 cSt 63148-62-9 2% component (ü) Decamethylcyclopen tasiloxane 4 cSt 541-02-6 22% Decamethyl · tetrasil · ox at 1.5 cSt 141-62-8 25% component (iü) cross-linked dimethylsiloxane compound firm resin 213629-14-2 3% component (iv) Trimethylsiloxy silicate firm resin 68988-56-7 15% (C30-45) alkyldimethylsilyl polypropylsilsequioxane Mp 63-71 ° C 955920-25-9 5% component (v) Glycerol dibehenate Pellet 91052-55-0 8th % Total: 100%

Component (i): Component (ii): Component (iii) Component (iv): silsesquioxane Component (v):

non-volatile polysiloxane compound volatile polysiloxane compound: cross-linked dimethylsiloxane compound organosiloxysilicate compound and OrganoGlycerin (C12-C26) ester compound

Example 6

Example 5 was repeated, the organosilsesquioxane compound from component (iv) being replaced by 3.5% trimethylstearyloxysilane (CAS No. 18748-98-6) in 3.5% stearyl alcohol (CAS No. 112-92-5) with an mp (of the mixture) of 5055 ° C was replaced and the polydimethylsiloxane compound with a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) was reduced to 18%.

Example 7

Example 6 was repeated, the polydimethylsiloxane compound having a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) being further reduced to 17% and a component (vi) in the form of 1% panthenol (CAS No. 8113-0) was added as a humectant.

BE2017 / 5566

2017/5566

Example 8

Example 6 was repeated, the polydimethylsiloxane compound having a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) being reduced further to 16% and

2% magnesium oxide (CAS No. 1309-48-4) was added.

Example 9

Example 8 was repeated, the polydimethylsiloxane compound having a viscosity of 100 cSt from component (i) (CAS No. 63148-62-9) being reduced to 15% and one

Component (vi) in the form of 1% panthenol (CAS No. 81-13-0) were added.

B E2017 / 5566

Claims (30)

Claims 1. A composition for use as a wound dressing to reduce and / or prevent scarring, comprising: (i) a non-volatile siloxane compound, preferably a linear or cyclic polydimethylsiloxane, with a weight fraction in the range from 5% by weight to 70% by weight; (ii) a volatile siloxane compound, preferably a linear and / or cyclic dimethylsiloxane compound, with a weight fraction in the range from 10% by weight to 80% by weight; and (iii) optionally a crosslinked siloxane compound, preferably a crosslinked dimethylsiloxane compound, with a weight fraction in the range from 1% by weight to 15% by weight; characterized in that this composition (iv) contains at least one organosiloxysilicate and / or an organosilsesquioxane compound, the proportion by weight of the organosiloxysilicate compound in the composition ranging from 5% by weight to 40% by weight, and the proportion by weight the organosilsesquioxane compound in the composition ranges from 2% to 30% by weight; (v) at least one glycerol (C ₁₂ -C ₂₆ ) ester compound, preferably as a monoester, diester and / or triester compound, and this glycerol ester compound in the composition in an amount in the range from 0.5% by weight to 20.0% by weight. -% is present; and (vi) optionally at least one humectant, as a single compound or as a mixture of such compounds, optionally in a mixture with water, preferably in an amount of 0.1% by weight to 5.0% by weight; such as B E2017 / 5566 (vii) optionally at least one pharmaceutical Active ingredient for the prevention or treatment of scars. 5 2. Composition according to claim 1, characterized in that the non-volatile linear siloxane compound [component (i)] of the compound of general formula (I): RR RR R1-Si-0 + SI-O-y-Si-0ärSi-R1 (0 RR R1 R corresponds to where R independently of one another is an alkyl radical which is optionally substituted by chlorine or fluorine and has 1-4 C atoms or phenyl, preferably methyl, ethyl, propyl or phenyl, 15 is preferably methyl; RI independently of one another means one of the meanings of R, hydrogen or hydroxyl, preferably methyl, ethyl, propyl, or phenyl, preferably methyl; m and n each independently an integer 20 from 10-2000, preferably an integer from 20 to 1500, and preferably an integer from 40 to 1000, in particular an integer from 60-1000; and the groups [-Si (R) (R) O-] and [-Si (R) (Ri) O-] in the molecule 25 are arranged in any order. Composition according to Claim 1 or 2, characterized in that the proportion by weight of the non-volatile siloxane compound [component (i)] is in the range from 10% by weight to 50% by weight, based on the total weight of the composition. B E2017 / 5566 4. Composition according to any one of claims 1-3, characterized in that the average molecular weight of the non-volatile linear siloxane compound [component ii)] in the range from l'OOO to 5,300,000, preferably in the range from 2,500 to 200,000. 5. Composition according to one of claims 1-4, characterized in that the kinematic viscosity at 25 ° C. 10 of the individual non-volatile linear siloxane compound [as part of component (i)] is in the range from 50 cSt (centistokes) to 120,000 cSt, preferably in the range from 50 cSt to 80,000 cSt. 15 6. Composition according to one of claims 1-5, characterized in that the volatile linear and / or cyclic siloxane compound [component (ii)] of the general formula (II), R R R R'-Si-O + Si-O-] _n Si- _R '(H) 20 R R R corresponds in which R and R 'independently of one another are an alkyl radical having 1-4 C atoms, preferably methyl; and 25 n is zero or an integer from 1-5, the two terminal substituents R 'together for the cyclic compound being the direct bond, i.e. form a cyclic polysiloxane compound. 30th 7. Composition according to any one of claims 1-6, characterized in that the proportion by weight of the volatile siloxane compound [component (ii)] in the Composition in the range of 15 wt .-% to 70 wt .-%, based on the total weight of the composition. B E2017 / 5566 8. Composition according to any one of claims 1-7, characterized in that the volatile linear siloxane compound is hexamethyldisiloxane, octamethyl5 trisiloxane, decamethyltetrasiloxane and / or dodecamethylpentasiloxane; preferably octamethyltrisiloxane and / or decamethyltetrasiloxane. 9. Composition according to one of claims 1-8, characterized 10 characterized that the volatile cyclic Siloxane compound hexamethylcyclotrisiloxane), octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane. 15 10. The composition according to any one of claims 1-9, characterized in that the crosslinked siloxane compound [component (iii)] which may be present is a crosslinked dimethylsiloxane compound, the proportion by weight of which in the composition is in the range from 1 20% by weight to 15% by weight, preferably in the range from 1% by weight to 10% by weight, is in each case based on the total weight of the composition. 11. The composition according to any one of claims 1-10, characterized 25 characterized in that the crosslinked silicone compound [component (iii}] which may be present has a kinematic viscosity (at 25 ° C.) in the range from 200,000 cSt to 900,000 cSt and the molecular weight of the crosslinked siloxane compound is higher than 200,000 Da 30 (Dalton), preferably higher than 250ΌΟΟ Da, and preferably higher than 300,000 Da. 12. The composition according to any one of claims 1-11, characterized in that the organosiloxysilicate compound [component (iv)] is a polyalkylpolysiloxysilicate η B Ε2017 / 5566, preferably a polymethylpolysiloxysilicate, preferably a trimethylsiloxysilicate. 13. The composition according to any one of claims 1-12, characterized 5 characterized in that the proportion by weight of the organosiloxysilicate compound in the composition is in the range from 5% by weight to 35% by weight, preferably in the range from 5% by weight to 30% by weight, based on the total weight the composition. 14. The composition according to any one of claims 1-13, characterized in that the organosilsesquioxane compound [component (iv)] is a polyalkylsilsesquioxane, a polyarylsilsesquioxane or a polyalkoxysilsesquioxane, 15, preferably a polyalkylsilsesquioxane, preferably a (C ₃₀ -C _4S ) alkyldimethylsilyl polyalkylsilsesquioxane, preferably a (C ₃₀ -C ₄₅ ) alkyldimethylsilylpolypropylsilsesquioxane. 15. The composition according to any one of claims 1-14, characterized in that the organosilsesquioxane compound has a melting point in the range from 60 ° C to 75 ° C, preferably in the range from 63 ° C to 71 ° C. 25th 16. The composition according to any one of claims 1-15, characterized in that the proportion by weight of the organosilsesquioxane compound in the composition is in the range from 5% by weight to 20% by weight, based on the total weight of the composition. 17. The composition according to any one of claims 1-16, characterized in that the glycerol (C ₁₂ -C ₂₆ ) ester compound [component (v)] is a glycerol (C ₁₈ -C ₂₄ ) ester compound, preferably glycerol behenate. B E2017 / 5566 18. The composition according to claim 17, characterized in that the glycerol (C ₁₂ ~ C ₂₆ ) ester compound is present as a mixture which consists predominantly of Diester connection exists. 19. Composition according to one of claims 1-18, characterized in that the glycerol ester compound is present in the composition in the range from 2.0% by weight to 15% by weight, calculated on the total weight of the composition. 20. The composition according to any one of claims 1-19, characterized in that the humectant [component (vi)] panthenol and related compounds, hyaluronic acid 15 and salts of this compound, as well as chemically related Glycosaminoglycan compounds, polyethylene glycol (PEG) and / or sorbitol, glycerin, urea, propylene glycol, pyrrolidone carboxylic acid and their salts, lactic acid and lecithins. 21. The composition according to claim 20, characterized in that the humectant in an amount of 0.1 wt .-% to 3.0 wt .-%, preferably in one Amount from 0.1% by weight to 2.0% by weight is present, 25 calculated on the total weight of the composition. 22. The composition according to any one of claims 1-21, characterized in that it contains one or more pharmaceutically active compounds [component (vii)] 30 contains antibacterial, anti-inflammatory, antiviral and / or antifungal activity, preferably with antibacterial and / or anti-inflammatory activity, preferably in an amount of 0.1% by weight to 5% by weight, based on the total weight 35 of the composition. B E2017 / 5566 23. Composition according to one of claims 1-22, characterized in that this composition contains further individual compounds or a mixture of compounds which act as thickeners / flow agents, 5 preferably a mixture consisting of stearyl alcohol (C ₁₈ H _3e O) and trimethylstearyloxysilane (C ₂ iH _4e OSi). 24. The composition according to any one of claims 1-23, characterized in that this composition is a 10 contains inorganic compound or a mixture of such inorganic compounds in the form of a fine powder, and these compounds are selected from metal oxides, metal carbonates and / or metal bicarbonates, preferably selected from zinc oxide, 15 titanium dioxide, magnesium oxide, calcium carbonate, magnesium carbonate, sodium carbonate and / or sodium bicarbonate. 25. The composition according to claim 24, characterized in that the powder or the powder mixture 20 is present in an amount of 0.1% by weight to 5% by weight, based on the total weight of the composition, and at least 75% of the particles of this powder or powder mixture have a diameter of less than 44 μm (micrometers). 26. The composition according to any one of claims 1-25, characterized in that it contains at least one UV-absorbing compound, preferably in an amount in the range from 10% by weight to 30% by weight. 30 based on the total weight of the composition. 27. The composition according to any one of claims 1-26, characterized in that it is in the form of an ointment or a gel with a kinematic viscosity in the range 35 from 1Ό00 cSt (Centistokes) to 25,000 cSt, preferably in the range from 5000 cSt to 15,000 cSt, measured with B E2017 / 5566 a device from Fisher Scientific, HAAKE RotoVisco 1 (Ser.No. 115000029002). 28. A process for producing a composition according to claims 1-27, characterized in that a non-volatile siloxane compound according to the definition of component (i); a volatile siloxane compound as defined in component (ii); an organosiloxysilicate and / or an organosilsesquioxane compound as defined in component (iv); a glycerol (C ₁₂ -C ₂₆ ) ester compound according to the definition of component (v), and optionally a crosslinked siloxane compound according to the definition of component (iii), and optionally further components which are to be present in the composition, in any order mixes until all components form a homogeneous composition. 29. The method according to claim 28, characterized in that [step (A)]: the non-volatile siloxane compound as defined in component (i); the organosiloxysilicate and / or the organosilsesquioxane compound according to the definition of component (iv), and any crosslinked siloxane compound present according to the definition of component (iii), are mixed intensively with one another at a temperature in the range from 70 ° C to 90 ° C until a homogeneous composition is obtained; then [step (B)]: the humectant of component (vi) which may have been present and which may have been mixed beforehand with water is added to the composition obtained in step (A) and the composition thus obtained at a temperature in the range from 70 ° C. to Homogenized at 90 ° C; subsequently B E2017 / 5566 [step (C)]: the superplasticizer, if any, and all the other components, if any, are added to the composition obtained in step (B) and the composition thus obtained at a 5 homogenize the temperature in the range from 30 ° C to 40 ° C and then allow it to cool to room temperature (20 ° C to 30 ° C); and then [step (D)]: the volatile siloxane compound according to the definition of component (ii) that according to step (C) 10 admits the composition obtained and the thus obtained Composition preferably homogenized at room temperature (20 ° C to 30 ° C). 30. The method according to claim 28 or 29, characterized 15 characterized in that the homogenization according to Step (A), step (B) and step (C), each carried out independently of one another, under reduced pressure, preferably at a pressure in the range from 300 mbar to 800 mbar, preferably in the range from 400 20 mbar to 600 mbar, the composition being mixed intensively in each case until a homogeneous composition is obtained. 31. Use of the composition according to one of the 25 claims 1-27 as a wound dressing for the treatment, in particular for the reduction and / or prevention, of scarring, preferably for the treatment of scars and the prevention of scar formation, in particular of hypertropic scars, atropic scars or 30 keloid scars, which result from a cut or Skin lesion have arisen. 32. A method of treating scars and reducing or preventing scarring, characterized in that an injured area of the B E2017 / 5566 human skin a composition according to the Claims 1-27 as a wound dressing. 2017/5566 BE2017 / 5566 Summary Composition for use as a wound dressing A composition for use as a wound dressing for the treatment, reduction and / or prevention of scarring, which contains the following components: a non-volatile siloxane compound; a fleeting one 10 siloxane compound; if necessary a cross-linked Siloxane compound; an organosiloxysilicate and / or an organosilsesquioxane compound; a glycerol (C12-C26) ester compound; optionally at least one humectant, optionally in a mixture with water, and optionally 15 at least one active pharmaceutical ingredient for the prevention or treatment of scars. £ urt> pSÎSÎÎiCÎ ftn «nt Office often« «wföp« 'e: n) $ Ri. brevets